Nvwm LLC Sells 313 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

by · The Cerbat Gem

Nvwm LLC lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,654 shares of the medical equipment provider’s stock after selling 313 shares during the quarter. Nvwm LLC’s holdings in Lantheus were worth $950,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Van ECK Associates Corp grew its holdings in shares of Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after purchasing an additional 21,604 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Lantheus by 56.0% during the third quarter. Harbor Capital Advisors Inc. now owns 128,913 shares of the medical equipment provider’s stock valued at $14,148,000 after buying an additional 46,262 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Lantheus by 226.7% during the third quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 526 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new stake in shares of Lantheus in the 3rd quarter valued at about $272,000. Finally, New York State Teachers Retirement System boosted its holdings in Lantheus by 3.3% during the 3rd quarter. New York State Teachers Retirement System now owns 91,568 shares of the medical equipment provider’s stock valued at $10,050,000 after acquiring an additional 2,902 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Down 1.7 %

Shares of NASDAQ LNTH traded down $1.86 during midday trading on Friday, hitting $107.98. 576,149 shares of the company traded hands, compared to its average volume of 509,573. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The firm has a market cap of $7.50 billion, a P/E ratio of 17.70 and a beta of 0.51. The stock has a 50-day moving average price of $108.13 and a 200 day moving average price of $94.63. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH – Get Free Report) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. During the same period in the prior year, the company posted $1.40 EPS. The firm’s revenue was up 22.5% on a year-over-year basis. As a group, analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of analyst reports. Truist Financial decreased their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. JMP Securities lowered their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Leerink Partners raised their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Finally, B. Riley increased their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $126.00.

Check Out Our Latest Research Report on LNTH

Insider Buying and Selling

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares in the company, valued at $9,540,682.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Further Reading

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).